Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
The racemic compound (R, S)-(±)-ibuprofen is a popular and well understood active pharmaceutical ingredient, but it has several disadvantageous formulation properties such as poor solubility, low melting point, and potential esterification with excipients containing an hydroxyl group. The authors investigate the use of an (R, S)-(±)-ibuprofen salt to evaluate these problems using various analytical methods to determine the polymorphism, crystallinity, and drying scheme.


Pharmaceutical Technology



Figure 1
The racemic compound (R,S)-(±)-ibuprofen or (R, S)-(±)-2-(4-isobutylphenyl) propionic acid is a popular active pharmaceutical ingredient (API) in analgesic, anti-inflammatory, and antipyretic therapies (1) with abundant information about the compound provided in the literature (2–11). Ibuprofen is marketed as a racemate. The enantiomer (S)-(+)-ibuprofen is the active agent and the other enantiomer, (R)-(–)-ibuprofen, is partially converted into (S)-(+)-ibuprofen in humans. (R,S)-(±)-ibuprofen has several disadvantageous formulation properties such as poor water solubility of less than 1 mg/mL at 25 °C, a low melting point of 77 °C, and possible esterification with excipients containing a hydroxyl group (1). These problems can be easily overcome by using an (R,S)-(±)-ibuprofen salt such as the racemic compound (R,S)-(±)-sodium 2-(4-isobutyl–phenyl) propionate dihydrate or (R, S)-(±)-sodium ibuprofen dihydrate (see Figure 1), whose potential values over (R,S)-(±)-ibuprofen make the study of its solubility, polymorphism, crystallinity, crystal habit, and drying scheme meaningful (12).

In this study, the solubility of (R, S)-(±)-sodium ibuprofen dihydrate solids at 25 °C was determined in 23 solvents using a robust and scalable initial solvent-screening method (13). Good solvents were identified, and the solubility curves of the solids in various good solvents were constructed. Good solvents were defined as solvents in which the solubility of racemic (R, S)-(±)-sodium ibuprofen dihydrate had a solubility of < 1 mg/mL at 25 °C. All solids were produced from the supersaturated solution of the good solvents by temperature cooling from 60–25 °C.

Differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and powder X-ray diffraction (PXRD) determined the polymorphism, crystallinity, and drying scheme of the solid samples (14). Optical microscopy (OM) and scanning electron microscopy (SEM) were used for crystal-habit imaging. The solids' solubilities and crystal habits were related to the solvent microscopic properties of dispersion forces (δd) polar forces (δp), and hydrogen bonding (δh) by the Hansen model adopted from the paint industry at 25 °C (15).

Solvent liquids generally are held together by van der Waals forces, which are electromagnetic interactions among molecules. The strength of van der Waals forces is directly reflected by the heat of vaporization (ΔHv). ΔHv can be translated into a correlation between vaporization and the solubility behavior because the types of intermolecular attractive forces needed to be overcome to vaporize a solvent liquid are the same as those that must be overcome to dissolve it. The Hildebrand numerical value (δt[Pa1/2 ]) of the solvency behavior of a specific solvent was invented as a function of ΔHv (15) in the following:











in which R is the gas constant (8.314 J/mol • K), T is the temperature (measured in K), and Vm is the molar volume (measured in m3 /mol).


ADVERTISEMENT

RELATED CONTENT
Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
Pfizer CentreSource Moves Forward with Asian Supply Pact
Opportunities Abound for Generic Drugs
Mapping a Biologics Supply Strategy
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
13%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
23%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients Insider Patricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
NSF, Microsoft Team in Cloud Computing
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here